Trial Profile
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary) ; Linezolid; Piperacillin/tazobactam
- Indications Bacterial infections; Nosocomial pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE-IMI 2
- Sponsors Merck Sharp & Dohme
- 24 Jun 2021 Results(n=433)evaluating treatment outcomes with IMI/REL in polymicrobial HABP/VABP based on data from the RESTORE-IMI 2 clinical trial presented at the World Microbe Forum 2021
- 25 Oct 2020 Results of an analysis assessing per-pathogen outcomes from this trial presented at the IDWeek 2020
- 25 Oct 2020 Results of subgroup analyses of critically ill patients presented at the IDWeek 2020